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ABSTRACT
Objectives: Polypharmacy is one of the main
management issues in public health policies because
of its financial impact and the increasing number of
people involved. The polymedicated population
according to their demographic and therapeutic profile
and the cost for the public healthcare system were
characterised.
Design: Cross-sectional study.
Setting: Primary healthcare in Barcelona Health
Region, Catalonia, Spain (5 105 551 inhabitants
registered).
Participants: All insured polymedicated patients.
Polymedicated patients were those with a consumption
of ≥16 drugs/month.
Main outcomes measures: The study variables
were related to age, gender and medication intake
obtained from the 2008 census and records of
prescriptions dispensed in pharmacies and charged to
the public health system.
Results: There were 36 880 polymedicated patients
(women: 64.2%; average age: 74.5±10.9 years). The
total number of prescriptions billed in 2008 was
2 266 830 (2 272 920 total package units). The most
polymedicated group (up to 40% of the total
prescriptions) was patients between 75 and 84 years
old. The average number of prescriptions billed
monthly per patient was 32±2, with an average cost of
€452.7±27.5. The total cost of those prescriptions
corresponded to 2% of the drug expenditure in
Catalonia. The groups N, C, A, R and M represented
71.4% of the total number of drug package units
dispensed to polymedicated patients. Great variability
was found between the medication profiles of men
and women, and between age groups; greater
discrepancies were found in paediatric patients
(5–14 years) and the elderly (≥65 years).
Conclusions: This study provides essential
information to take steps towards rational drug use and
a structured approach in the polymedicated population
in primary healthcare.
INTRODUCTION
Polymedication is becoming an increasingly
important issue in public health policies and
it may have a negative impact on patients
and the healthcare system.1 Among the
reasons that contribute to the increase in
polymedication are the ageing population,
the prevalence of chronic diseases and the
increased availability of drugs and access to
healthcare services.2 3
In quantitative terms, polymedication is
deﬁned as various drugs taken simultan-
eously by the same user.4 Although there is
no consensus on the number of drugs a
patient must take to be classiﬁed as polyme-
dicated, four or more seems to be the
accepted ﬁgure in most cases.5 However,
several studies suggest that the average
number of drugs consumed daily by the
elderly is 4.2–8,6–8 with a maximum of 17 dif-
ferent drugs/day.7
In general, polymedication is more
common among women, institutionalised
patients and in rural areas, and is directly
related to the number of prescribers.9–11 In
addition, comorbidities increase with age and
the number of drugs prescribed.12 13 Hence,
there is an increased risk of medication-
related problems that can cause treatment
failure, poisoning and an increased number
of hospital admissions.5 13 14
Strengths and limitations of this study
▪ This study includes 1-year monitoring of a large
sample size, and provides a way to examine drug
use under real-life situations, linked to practice
through the prescriber and also to the patient.
This information is essential in order to take
steps towards rational drug use and a structured
approach in the polymedicated population.
▪ Administrative information systems are not
perfect and could limit the measurement of data
quality in electronic records.
▪ Information related to prescription rates and
costs should be viewed cautiously, due to the
different forms of presentation and costs of med-
icines in other countries.
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At the very least, periodically reviewing the treatment
regimen of polymedicated patients may prevent these
several problems and help professionals rationalise the
use of medication.11 14 15 Thus, implementing pro-
grammes to analyse and support polymedicated patients
has become one of the priorities of the various national
health services,16–20 including the Spanish National
Health Service14 and the regional health administrations
of Spain. However, no studies to describe the pattern of
consumption in Spain have been carried out till today.
A suitable setting for the consideration of the wide
range of issues related to polypharmacy is the Barcelona
Health Region (BHR). This region’s population lives in
both rural and urban areas and has access to various
types of healthcare services.21 Thus, the objectives of
this study were ﬁrst to determine the number and preva-
lence of polymedicated patients receiving 16 or more
medications in the public healthcare system in BHR, in
order to describe the proﬁle of polymedicated patients
and identify their costs. Second, to describe the medica-
tions prescribed in the study population, differentiated
by age and gender.
METHODS
Design and setting of the study
A cross-sectional observational study of all the insured
polymedicated patients in 2008. The study was per-
formed in the ﬁeld of primary healthcare and, speciﬁc-
ally, in BHR.
Data source
The study used population data from the 2008 Catalonia
census.22 According to the census, BHR had 5 105 551
registered inhabitants, 2 604 190 (51% of the total) of
whom were women, accounting for 68% of the total
population of Catalonia. The age distribution of this
region population showed predominance of adults (34%
of the population was between 25 and 44).
Records of billed prescriptions dispensed in pharma-
cies and charged to the Catalan Health Service were
also utilised. This information was obtained by means of
the personal healthcare card, the document that pro-
vides citizens with access to the centres, services and pro-
visions of the public health system (these services
include drugs subsidised by the Catalan Health Service).
This information is stored monthly in a computer
system, which allows the information required for the
management and monitoring of pharmaceutical services
to be designed and collected.
Data collection and variables
A polymedicated user in the present study was deﬁned
as someone receiving 16 or more active principles in a
month. The control of the polymedicated population in
Catalonia and each health region (number of users and
drug consumption bill) following this criteria is part of
the Efﬁciency Indicators in Primary Care, and is
periodically evaluated by an internal Management
Committee in the Catalan Health Service (macroman-
agement level). Concurrently, each health region team
is also involved in limiting the polymedication approach
to the needs and priorities for all indicators to be
improved (micromanagement level). In case of BHR,
and according to the 2008 objectives, this indicator was
working at the level of each primary care team or capita-
tion area, and referred to each provider. In such cases of
high-risk polymedicated patients, a diagnostic justiﬁca-
tion was required by the BHR team.
The data collected from the proﬁles of the polymedi-
cated patients were gender and age. Nine age groups
were established (5–14, 15–24, 25–34, 35–44, 45–54,
55–64, 65–74, 75–84 and more than 84 years). In terms
of drugs consumption, the following were identiﬁed:
number of prescriptions billed, number of package units
dispensed, total cost of medications dispensed and
the amount ﬁnanced by the Catalan Health Service (the
total cost of medications dispensed minus the out-of-
pocket amount paid by the patients). A package unit is
deﬁned as a standard package of a medication dis-
pensed to a patient (prepared by the manufacturers),
which does not necessarily coincide with the number of
medication units required by the patient. A set of indica-
tors was then obtained: the number of prescriptions per
user, the number of package units dispensed per user,
the total cost of drugs dispensed per user, the number
of prescribers (that prescribed at least one drug) and
the level of copayment by the patient at the time of dis-
pensing in the pharmacy.
A descriptive study was conducted simultaneously on the
types of drugs prescribed in order to characterise the
general therapeutic proﬁle of the study population
(number of prescriptions and number of package units
dispensed). The drugs were grouped based on the
Anatomical-Therapeutic-Chemical Classiﬁcation System.23
Literature review
A systematic search was conducted (April 2013) through
database PubMed to identify the available evidence on
the prevalence and medication proﬁle of polymedicated
users, as well as the cut-offs indicating multiple drug use.
The terms to run the search were located by the vocabu-
lary Medical Subject Headings, with which the articles
are indexed in the MEDLINE database. In order to com-
plete this search and extend the results, additional
searches combining free terms were also conducted. All
search strategies (7) resulted in 2188 references. The
studies identiﬁed through this search were evaluated by
two independent reviewers to assess their inclusion in
this document.
Data analysis
A database was designed. Analysis of variance and
Student t tests were used to determine the statistical sig-
niﬁcance (p<0.05) of the differences between popula-
tion subgroups using the SPSS V.20.0 statistics program.
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RESULTS
Description of the polymedicated patients
The number of polymedicated patients in BHR in 2008
was 36 880 (0.72% of the total population in BHR) and
accounted for 78% of the polymedicated population of
Catalonia in 2008; 1 of every 43 ﬁlling prescriptions met
the criteria for polymedication in BHR. The monthly
average of polymedicated patients with these characteris-
tics was 5983±1448. Table 1 shows the total number of
polymedicated patients and the number of prescriptions
with the 2008 monthly changes (increase or decrease)
in BHR.
Table 2 shows the percentage distribution, by gender
and age group, of the polymedicated population and
the total population in BHR. The average age of the
36 880 patients was 74.5±10.9 years (the full range was
9–108 years) and more than two-thirds of them were
women (64.2%). It is noteworthy that 67% of the poly-
medicated patients were between 65 and 84 years. After
individually analysing nine age groups, there appeared
to be signiﬁcant differences in the mean age between
men and women in all age groups (p<0.05), except
between 25 and 34, 45 and 54, 55 and 64 years.
Indicators of drug consumption
The total number of prescriptions for polymedicated
patients billed to BHR in the year of study was 2 266 830
(2 272 920 total package units; 2 110 290 were drug
package units), and the average number of prescriptions
dispensed per month was 182 722±36 991. When these
items were analysed by age group, the maximum
number of prescriptions billed was by patients between
75 and 84 years, the most polymedicated group (up to
40% of the total prescriptions billed). In groups of
patients older than 84, the number of prescriptions
decreased relevantly.
Overall, the average number of prescriptions billed
monthly per patient was 32±2, and the average cost per
patient per month was €452.7±27.5. The number of pre-
scriptions billed per patient increased with the age
group (up to 45–54 years). After examining the values
for the different months, the average rate of increase
Table 1 Polymedicated patients and the number of prescriptions in Barcelona Health Region (BHR) with their monthly
changes in 2008
Month (2008)
Users Monthly evolution (% users)
Prescriptions billedTotal Men Women Total Men Women
January 8160 2962 5198 31 −7 −7 251 033
February 7407 2659 4748 −9 −10 −9 223 772
March 7029 2578 4451 −5 −3 −6 212 659
April 8136 2864 5272 16 11 18 247 206
May 6470 2270 4200 −20 −21 −20 192 904
June 5691 1995 3696 −12 −12 −12 168 492
July 5553 1976 3577 −2 −1 −3 186 820
August 4034 1437 2597 −27 −27 −27 139 117
September 4396 1528 2868 9 6 10 150 538
October 5631 1986 3645 28 30 27 191 498
November 4762 1699 3063 −15 −14 −16 155 846
December 4525 1635 2840 −5 −4 −7 146 945
Total number of prescriptions billed was 2 266 830.
Table 2 Distribution of polymedicated patients and residents in Barcelona Health Region (BHR), by gender and age group
Age group (years)
Users (%) Population (%) Difference (%)
Total Men Women Total Men Women Total Men Women
5–14 0 0 0 9.8 5 4.7 −9.8 −5 −4.7
15–24 0.1 0 0 10.2 5.2 5 −10.1 −5.2 −5
25–34 0.2 0.1 0.2 17.5 9 8.5 −17.3 −8.9 −8.3
35–44 1.1 0.4 0.7 16.6 8.5 8.1 −15.5 −8.1 −7.4
45–54 3.3 1.2 2.1 13.1 6.4 6.7 −9.8 −5.2 −4.6
55–64 11 4.2 6.8 11.1 5.3 5.8 −0.1 −1.1 1
65–74 27.1 10.4 16.7 8.1 3.7 4.4 19 6.7 12.3
75–84 39.9 14.4 25.5 6.1 2.4 3.7 33.8 12 21.8
>84 17.3 5.1 12.2 2.1 0.6 1.5 15.2 4.5 10.7
The “% Users” represents the percentage of polymedicated patients in each age group, followed by gender breakdown, with respect to the
total number of polymedicated patients in BHR. The “% Population” represents the percentage of people per age group and by gender with
respect to the total population of that region. The ‘Difference (%)’ is ‘% Population’ subtracted from ‘% Users’ for each age group and by
gender.
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in billed prescriptions between the age groups (up to
45–54 years) was 9±12.3 prescriptions per patient.
However, in age groups above 45–54 years, this rate of
increase began to stabilise and started to decrease at a
rate of –3±1 prescriptions billed per patient. The cost
per patient followed this same pattern, but the cost
started to decrease earlier, starting from the 35–44 age
group at a rate of €−70±29/patient.
The number of prescribers that issued at least one pre-
scription varied each month depending on the age and
gender of the patients. The monthly average was 3±2
prescribers/patient/month, and 0.3% of patients were
prescribed by 10 or more physicians/month. Elderly
patients between 65 and 84 (p<0.05) and women
(p<0.05) made the greatest number of visits to health-
care professionals.
With regard to the copayment level applied to the
patient at the time of dispensing, 95.5% of users were
exempt from payment (retirees). In 2008, the Catalan
Health Service funded 97% of the total cost of medica-
tions. BHR accounted for 69% of the drug expenditure
in Catalonia; of this percentage, 2% corresponded to
the total cost of prescriptions for polymedicated patients
in the region.
Descriptive analysis of medications prescribed for
polymedicated patients
The online supplementary appendix 1 shows the distri-
bution of drug use by age groups among polymedicated
patients in BHR. Since the range of prescription drugs
was widespread, they were classiﬁed according to the
main anatomical group and therapeutic subgroup to
minimise variability and to improve the readability of
the results. The ﬁve main groups (N, C, A, R and M)
represented 71.4% of the total number of drug package
units dispensed. Women followed the same pattern as
above (group N 15.8%; group C 13.2%; group A 10.8%
and group R 5.1% of the total drug package units dis-
pensed). However, in men, group C drugs (8.9% of the
total drug package units dispensed) ranked ﬁrst, fol-
lowed by groups N and A (7% and 5.9% of the total
drug package units dispensed, respectively).
The monthly average of the various active principles
dispensed to polymedicated patients in BHR was 1536±42
(peaking in February with 1599 through December with
1476). In general, women had a higher monthly average
of prescriptions (different active principles; 799±22). The
25 most commonly used active principles by polymedi-
cated men and women in BHR in 2008 represented
about 40% of the total drug package units dispensed
(40.3% in women and 38.6% in men). The online
supplementary appendix 2 shows the full set of results.
Some peculiarities were observed when determining
the drugs most frequently prescribed for polymedicated
patients; they were differentiated by age group, because
the pathologies affecting each population are distinct. In
children between 5 and 14 years, nearly 30% of the med-
ications dispensed were losartan, paracetamol and
omeprazole; losartan was the most frequently prescribed
medication (9% of all prescriptions in this age group).
A change in the consumption patterns of polymedicated
patients was observed starting from patients between the
ages of 45 and 54, where the number of prescriptions
for drugs such as metformin, enalapril, furosemide and
aspirin progressively increased. Consumption of group N
drugs in users between 65 and 74 years started decreas-
ing to 21.7% of the total medication dispensed, whereas
group C drugs started increasing (22.8% of the medica-
tion dispensed), turning out to be the most dispensed
drugs.
Signiﬁcant differences were observed between the
medication proﬁles of polymedicated men and women.
In men, the two most commonly prescribed drugs were
omeprazole and paracetamol, while in women the order
was reversed. The most distinguishing feature between
men and women was that some chemical subgroups
were consumed more by one gender than the other. For
example, respiratory drugs were predominant in men, as
were antithrombotic agents and vasodilators for coron-
ary disease, such as organic nitrates.
In general, polymedicated patients had a high con-
sumption of anxiolytics, antidepressants, and hypnotics
and sedatives, which correspond to 9.4% of the total
drug package units dispensed (4.4%, 3.4% and 1.6%,
respectively, for each group). Women, who represented
45% of the users of these drugs, simultaneously con-
sumed these three groups of drugs in 2008. Speciﬁcally,
80% of women consumed anxiolytics, sedatives or hyp-
notics, while 61% consumed antidepressants. In con-
trast, the consumption among polymedicated men was
69% and 42%, respectively, and concurrent use of all
three groups of drugs was only 29%.
DISCUSSION
The cut-off established in this study to determine the
number of polymedicated patients in BHR is not com-
monly used in the published literature available.
Regarding the number of active principles dispensed
monthly (≥16), as explained in methods, it is an oper-
ational indicator that gives rise to intervention and
therefore prioritises that number to inﬂuence in that
population with potentially greater risk. Besides, due to
the volume of data and the subsequent processing and
management in the health region, it is unfeasible to
consider patients consuming less than this ﬁgure. As far
as the outcome of consumption is concerned, the
number of package units dispensed is the most used
indicator by the Catalan Health Service to calculate the
total pharmaceutical expenditure of this population and
in consequence the impact on the public health budget
of BHR.
After a literature review of 2188 references, only 12 of
the studies which met the inclusion criteria considered a
cut-off of 10 or more drugs, and only one of them followed
a similar approach and criteria as ours (polypharmacy
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cut-off ≥15 drugs).24 In general, many patients receive pre-
scriptions for a large number of drugs, both in our health-
care system and in that of other western countries.
Obviously, this situation can be observed more commonly
in elderly patients, who require special monitoring, revi-
sions and adjustment of their prescribed medications, for
both clinical and expenditure implications.1
This study was conducted in BHR due to its size (68%
of total population in Catalonia), density of population
(1606 inhabitants/km2), extension (3179 km2) and sub-
sequent high consumption of medicines observed. In
addition, population distribution by age and gender is
similar in both BHR and Catalonia. This region has the
largest number of polymedicated patients in Catalonia,
representing 78% of the total polymedicated patients in
2008.22 Data accumulated by the Catalan Health Service
concerning polymedication issues show that the ﬂuctu-
ation in the number of prescriptions follows a seasonal
pattern.25 Throughout the year the number of prescrip-
tions increased in January, June and October, mainly
due to visits to physicians before ( June) and after
( January and October) the holiday period. In addition,
the increase in prescriptions in April was due to the
annual review of the reference pricing system by the gov-
ernment,26 27 which reduces the price of drugs from
year to year. The new prices came into effect in May and
therefore the turnover rate in pharmacies increased
(and thus the number of patients and billed prescrip-
tions) in the previous month.
According to published population studies, polymedi-
cated patients are mostly women over 65 with multiple
chronic diseases, frequent exacerbations and severe
comorbidities, all of which imply a greater consumption
of different medications and more frequent visits to
health centres to collect prescriptions and/or consult
physicians.10 17 28 Younger and more elderly patients
(5–14 and >84 years, respectively) are fewer in number
and consume fewer medications with respect to the
number of prescriptions and drugs dispensed.29 30 In
contrast, some European studies, such as one by
Linjakumpu et al10 in Finland, showed an increased
medication consumption in patients over the age of 84.
The data on drugs most commonly used by polymedi-
cated patients in BHR describe their typical medication
proﬁle. However, there is great variability in the types of
medications these patients consume and it is not mini-
mised when drugs are classiﬁed by the therapeutic sub-
group. Logically, the most speciﬁc classiﬁcation, that is,
classiﬁcation by chemical substances, will further
increase the variability of the medication proﬁle.
According to other studies on drug consumption among
the general population, the main anatomical groups
with the highest consumption are similar to this study
(N, C, A, R and M).31 In polymedicated patients, these
ﬁve groups accounted for 71.4% of the total package
units dispensed. Speciﬁcally, omeprazole and paraceta-
mol were the two most frequently consumed drugs (8%
in men and 10% in women).
The study shows that consumption of antidepressants,
hypnotics and sedatives, and anxiolytics, is a typical indica-
tor of polymedicated patients and is especially signiﬁcant
among women, 45% of whom used at least two of these
groups concurrently in 2008. The literature also indicates
that the consumption of these drugs is higher among
women and can be explained, among others, by their self-
perceived poorer state of health and the high prevalence
of mental illness and musculoskeletal problems.32–34
Despite the importance of polymedication, there is
little information on the use of drugs in population sub-
groups. The majority of previous studies have focused
on analysing expenditure by indirectly studying drug
consumption based on the amount sold, population
health surveys and home medication cabinets.35 36
Our study has several limitations. Administrative infor-
mation systems are not perfect and could limit measure-
ment of data quality in electronic records. This aspect
should be taken into account when generalising our
results. On the other hand, this study includes a large
sample size and provides a way to examine drug use
under real-life situations (linked to practice through the
prescriber and also to the patient) that potentially
increase generalisability. Besides, the information related
to prescription rates and costs should be viewed cau-
tiously, as, due to the different forms of presentation
and costs of medicines, this information cannot easily be
extrapolated to other countries. This would not be the
case nationally, as medicines are standardised through-
out the whole of Spain. In addition, we did not have
access to clinical data, such as medical conditions to
determine whether prescribing practices were clinically
appropriate.
To conclude, this study provides results concerning
the prevalence of polymedicated users in the public
healthcare system in Catalonia and shows that the
general proﬁle is a woman over 65 with chronic diseases
and comorbidities that involve a high consumption of
different drugs and thus a higher cost to the healthcare
system, in contrast to younger and more elderly patients.
This information is essential in order to take steps
towards rational drug use and a structured approach in
the polymedicated population. These may be practices
based and should take into account factors such as age,
gender and clinical conditions.
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